Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05391906
• Other study ID #: TiffanySo
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 30, 2023
• Est. completion date: December 30, 2026

Study information

• Verified date: February 2024
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intravoxel incoherent motion (IVIM) is technique based on diffusion-weighted imaging (DWI). In this study, the investigators evaluate the use of IVIM in patients with Multiple Sclerosis.

Description:

Intravoxel incoherent motion (IVIM) is technique based on diffusion-weighted imaging (DWI), it is achieved through an MRI acquisition with multiple small b value to extract perfusion data. It has been shown to be a promising technique in evaluation of many brain conditions. This study seeks to assess intravoxel incoherent motion (IVIM) parameters in characterizing plaques and specific tissues in multiple sclerosis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: December 30, 2026
• Est. primary completion date: December 20, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients who are 18 years or older.

2. Relapsing-remitting MS diagnosed as per Macdonald criteria

Exclusion Criteria:

1. Contraindication to MRI. For example, metal implantation in the body, claustrophobia and pregnancy.

2. Patients who are unable to tolerate the scans without moving the head as a result of symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive impairment, coughing, and shortness of breath.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Other:
• Diffusion-weighted magnetic resonance imaging
Diffusion-weighted magnetic resonance imaging

Locations

Country	Name	City	State
Hong Kong	CUHK	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IVIM parameters (including ADC,D,D*,f) in Multiple Sclerosis brain regions.	Primary Outcome Measure: 1. IVIM parameters (including ADC,D,D*,f) in Multiple Sclerosis brain regions. The parameters are calculated based on a IVIM model bi-exponential model represented by: S(b)/S(0)=f ×exp(-bD*)+ (1-f)×exp(-bD), and the mono-exponential model for ADC calculation as represented by: S(b)/S(0)=exp(-bADC), where S(b) and S (0) are the MRI signal intensities at a given b value and b = 0, respectively.; ADC: apparent diffusion coefficient. ADC is expressed in units of mm2/s.; f: the perfusion or (micro) vascular volume fraction which depends on capillary geometry and blood velocity. f is expressed in units of mm2/s.; D*: pseudo diffusion coefficient that resembles the perfusion related incoherent microcirculation. D* is expressed in units of mm2/s.; D: pure diffusion coefficient which is related to pure molecular diffusion. D is expressed in units of mm2/s.	Up to 2 months